Journal
CURRENT OPINION IN ONCOLOGY
Volume 19, Issue 4, Pages 328-335Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cco.0000275309.58868.11
Keywords
-
Categories
Ask authors/readers for more resources
Key points (1) Neutropenia is a frequent complication of chemotherapy associated with life-threatening infections, hospitalisation, and chemotherapy dose reductions and delays. (2) Primary prophylaxis with granulocyte colony stimulating factors has been shown to reduce the incidence and duration of neutropenia, febrile neutropenia, infections hospitalisation and antibiotic use. (3) Recent randomised clinical trials of filgrastim, lenograstim and pegfilgrastim showed variable results across patient groups at different risks of febrile neutropenia. (4) Pegfilgrastim is at least as effective as filgrastim in the prophylaxis of chemotherapy induced neutropenia and has improved pharmacokinetics requiring reduced administration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available